Hoag was well represented at the 2024 Medical Innovation conference, presenting on topics including Regenerative Medicine and Wearables for Monitoring and Managing Cancer. Christopher Duma, MD, FACS, discussed stem cell therapies for treating neurodegenerative diseases like Alzheimer's and ALS. He highlighted Hoag's clinical trial that introduces stem cells into the brain's ventricles. Future developments may include allogenic stem cell treatments—where cells from one person are processed and transferred to others. However, social acceptance remains crucial for advancing these therapies. Michael Brant-Zawadzki, M.D., F.A.C.R., Vice President of Clinical Research Administration, CATALiST and Addiction Services and Charles De Mesa, DO, Chief of Interventional Pain, Physical Medicine & Rehabilitation for Hoag Spine Institute, explored how wearables are revolutionizing cancer treatment. These devices offer non-invasive solutions for patients suffering from chemotherapy-induced neuropathy, using low-intensity multidirectional magnetic fields to reduce neuroinflammation. Neuromodulation treatments, both pharmaceutical and non-pharmaceutical, are tailored to individual needs, particularly for vulnerable populations like cancer patients. The affordability and scalability of wearables allow physicians to provide comprehensive treatment and pain management. The presenters emphasized that pain affects multiple aspects of a patient's life—psychological, emotional, physiological, and social. Chronic pain can lead to anxiety and fear, potentially impacting mental health and increasing addiction risk. By addressing these interconnected issues, wearable technology offers a promising approach to enhancing cancer patients' quality of life.
-
-
-
-
-
+3